In Q1 2019 Immunicum reports, a net result of SEK -29m and a cash position of SEK 393m (last of March), which was in line with our expectations. Significant milestones are approaching, with GIST trial readout expected to be announced in mid-2019 and MERECA topline results expected in Q3 2019.